Lonza Group steady on SIX, consensus view underpins the stock

By Daniel Hoffmann, Chart & Technicals desk. Reviewed prior to publication on 2026-06-26, 07:04.

Lonza Group AG (CH0013841017) remains a key Swiss healthcare supplier for global pharma and biotech clients. The stock trades on SIX Swiss Exchange, where analysts continue to assess its contract manufacturing exposure to biologics and small molecules based on recent consensus data from MarketScreener and other platforms.

Analyst consensus on Lonza

Recent overview pages for Lonza on MarketScreener and similar analyst aggregation services show that a majority of brokers still rate the shares at Buy or Outperform, while a minority advise Hold, reflecting confidence in the contract development and manufacturing organization (CDMO) model. A consensus 12-month price target remains above the current market price in Swiss francs, according to these summaries, suggesting that most covering houses expect further upside over time.

Analyst commentary from large investment banks such as UBS and JPMorgan in recent months has highlighted Lonza's position in biologics manufacturing, pointing to a robust medium-term growth pipeline tied to monoclonal antibodies and emerging modalities. These notes also flag execution risks around new plant ramp-ups and pricing pressure from large pharmaceutical clients, which are factored into their valuation models.

How Lonza makes its money

Lonza Group AG primarily generates revenue as a contract development and manufacturing organization for the pharmaceutical and biotechnology industry. Its activities span development services, clinical and commercial-scale production of active pharmaceutical ingredients, and specialized delivery technologies for complex biologics and small-molecule drugs.

What the company sells

One representative Lonza offering is its mammalian cell culture-based biologics manufacturing platform, which supports pharmaceutical companies in producing monoclonal antibodies and other complex biologic medicines at clinical and commercial scale. These services provide long-term, capacity-based revenue streams tied to customers' approved and pipeline therapies.

Where the stock trades today

Lonza Group AG shares trade on SIX Swiss Exchange in Zurich under the ticker LONN, quoted in Swiss francs, with investors monitoring the stock as part of the broader European healthcare and CDMO peer group including players such as Catalent and Siegfried.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.